Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Jeffries Keeps Underperform on AaiPharma


Jeffries keeps its underperform rating on aaiPharma (AAII).

AaiPharma says its 10-K report won't be filed, as planned, by the extension deadline. The stock is subject to delisting. Analyst David Windley says this will trigger defaults on the company's debt, and could precipitate defaults on its senior subordinated notes as well.

He says an independent inquiry is potentially expanding into all of 2003, vs. the second-half of 2003 only. He had believed all along that aaiPharma's problems started before mid-year last year.

Windley cut the price target to $7, from $4. He sees 68 cents 2004 earnings per share, and 52 cents in 2005. Windley thinks aaiPharma is a falling knife; it's hard to know where the bottom is. He suggests that those uninvolved stay that way.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus